Brain Cancer

- **Gloma**
  - Glioblastoma
  - IDH mutant glioma

- **Meningioma**
  - Recurrent high-grade radiation-relapsed meningioma

**ETCTN Trials by Disease/Treatment Area: Brain Cancer**

- **10129**: A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors (3 Cohorts: glioma, cholangiocarcinoma, other solid tumors)
- **10186**: A Phase III Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
- **10505**: A Phase 1/2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma

**NOTE:** *No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: July 17, 2022*